ADVERTISEMENT

ASH 2021 — LentiGlobin improves quality of life up to 24 months in sickle cell disease.

Daniela Ovadia — Agenzia Zoe   |   Conference Report   |   16 December 2021
ADVERTISEMENT

by Massimo Sandal (Agenzia Zoe)

Takeaway messages

  • LentiGlobin gene therapy improves quality of life (QoL), pain and fatigue in sickle cell disease (SCD) up to 24 months after treatment.

 

Why this matters

          

March Challenge

Ends in 11d 14h
left
right

Topic Challenges

left
right